April 26, 2018 | The gene-editing technology CRISPR-Cas9 has captured the world’s attention with the possibility of fixing tough diseases and altering human traits. While experimental medicine, ethical worries, and an epic patent battle have attracted most of the headlines, the field’s pioneers have advanced new types of CRISPR to detect and diagnose diseases. Enter, a new diagnostics company called Mammoth Biosciences, which has licensed technology from the lab of Jennifer Doudna of the University of California, Berkeley. Xconomy